Two-Hour Session Will Feature Two Live Cases; Pooled Analysis of Bifurcation Stent System Will
Examine Evidence from Eight Clinical Studies

Durham, N.C. – Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced activities highlighting the latest experience with the TRYTON Side Branch Stent at EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions, taking place at the Palais des Congrès May 15-18, 2012 in Paris. Read More…

Company gains first and only commercially available subcutaneous ICD technology to offer lifesaving therapy to patients at risk of sudden cardiac arrest

NATICK, Mass.,  — Boston Scientific Corporation (NYSE: BSX) announces the exercise of its option to acquire Cameron Health, Inc., a privately held company based in San Clemente, California. Cameron Health has developed the world’s first and only commercially available subcutaneous implantable cardioverter defibrillator – the S-ICD® System. Read More…

MURRAY HILL, N.J.–(BUSINESS WIRE)–C. R. Bard, Inc. (NYSE: BCR) today announced that it has acquired Lutonix, Inc. for a purchase price of approximately $225 million paid at closing Read More…

Lead Program Includes Novel Investigational Compound for Prevention/Treatment of Skin Scarring

NEW YORK & SAN DIEGO–Pfizer Inc. (NYSE: PFE) and Excaliard Pharmaceuticals, Inc. announced today that they have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. Read More…